137 related articles for article (PubMed ID: 37003878)
41. Genetic features of TP53 mutation and its downstream FOXA1 in prostate cancer.
Xu X; Xie L; Meng L; Geng S; Liu J; Cao X; Dong Z; Xing Z
Biosci Trends; 2022 Jul; 16(3):221-229. PubMed ID: 35768267
[TBL] [Abstract][Full Text] [Related]
42. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
[TBL] [Abstract][Full Text] [Related]
43. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
44. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract][Full Text] [Related]
45. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Stopsack KH; Nandakumar S; Wibmer AG; Haywood S; Weg ES; Barnett ES; Kim CJ; Carbone EA; Vasselman SE; Nguyen B; Hullings MA; Scher HI; Morris MJ; Solit DB; Schultz N; Kantoff PW; Abida W
Clin Cancer Res; 2020 Jul; 26(13):3230-3238. PubMed ID: 32220891
[TBL] [Abstract][Full Text] [Related]
46. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
Beltran H; Wyatt AW; Chedgy EC; Donoghue A; Annala M; Warner EW; Beja K; Sigouros M; Mo F; Fazli L; Collins CC; Eastham J; Morris M; Taplin ME; Sboner A; Halabi S; Gleave ME
Clin Cancer Res; 2017 Nov; 23(22):6802-6811. PubMed ID: 28842510
[No Abstract] [Full Text] [Related]
47. Comprehensive Mutation Profiling of Colorectal Cancer Patients With Lung or Liver Metastasis by Targeted Next-Generation Sequencing.
Hu CT; Wang JL; Hou T; Yan ZW; Zu LD; Fu GH; Shen WW
Technol Cancer Res Treat; 2023; 22():15330338231185285. PubMed ID: 37394872
[TBL] [Abstract][Full Text] [Related]
48. Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y; Zhang T; Wang B; Pan J; Jin S; Fang B; Gu W; Qin X; Dai B; Lin G; Gan H; Wu J; Ye D; Zhu Y
Mol Oncol; 2023 Oct; 17(10):2183-2199. PubMed ID: 37584393
[TBL] [Abstract][Full Text] [Related]
49. Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites.
Tappero S; Piccinelli ML; Incesu RB; Cano Garcia C; Barletta F; Morra S; Scheipner L; Baudo A; Tian Z; Parodi S; Dell'Oglio P; de Cobelli O; Graefen M; Chun FKH; Briganti A; Longo N; Ahyai S; Carmignani L; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):47-55.e2. PubMed ID: 37690970
[TBL] [Abstract][Full Text] [Related]
50. Evolution of structural rearrangements in prostate cancer intracranial metastases.
Khani F; Hooper WF; Wang X; Chu TR; Shah M; Winterkorn L; Sigouros M; Conteduca V; Pisapia D; Wobker S; Walker S; Graff JN; Robinson B; Mosquera JM; Sboner A; Elemento O; Robine N; Beltran H
NPJ Precis Oncol; 2023 Sep; 7(1):91. PubMed ID: 37704749
[TBL] [Abstract][Full Text] [Related]
51. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
[TBL] [Abstract][Full Text] [Related]
52. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.
McKay RR; Kwak L; Crowdis JP; Sperger JM; Zhao SG; Xie W; Werner L; Lis RT; Zhang Z; Wei XX; Lang JM; Van Allen EM; Bhatt RS; Yu EY; Nelson PS; Bubley GJ; Montgomery RB; Taplin ME
Clin Cancer Res; 2021 Jul; 27(13):3610-3619. PubMed ID: 33849963
[TBL] [Abstract][Full Text] [Related]
53. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
Cyrta J; Prandi D; Arora A; Hovelson DH; Sboner A; Rodriguez A; Fedrizzi T; Beltran H; Robinson DR; Gopalan A; True L; Nelson PS; Robinson BD; Mosquera JM; Tomlins SA; Shen R; Demichelis F; Rubin MA
J Pathol; 2022 Jul; 257(3):274-284. PubMed ID: 35220606
[TBL] [Abstract][Full Text] [Related]
54. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
55.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
56. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
[TBL] [Abstract][Full Text] [Related]
57. Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer.
Dincman TA; Karam JAQ; Giordano A; Li H; Drusbosky LM; Gourdin TS; Howe PH; Lilly MB
Front Oncol; 2023; 13():1202277. PubMed ID: 38450313
[TBL] [Abstract][Full Text] [Related]
58. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract][Full Text] [Related]
59. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
[TBL] [Abstract][Full Text] [Related]
60. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]